Description: Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
Home Page: www.sprucebiosciences.com
SPRB Technical Analysis
2001 Junipero Serra Boulevard
Daly City,
CA
94014
United States
Phone:
415 655 4168
Officers
| Name | Title |
|---|---|
| Mr. Michael G. Grey | Exec. Chairman |
| Mr. Samir M. Gharib CPA, CPA, M.B.A. | Pres & CFO |
| Dr. Javier Szwarcberg M.D., M.P.H. | CEO & Director |
| Dr. Ralph William Charlton III, M.D. | Chief Medical Officer |
| Dr. Libbie Mansell M.B.A., Ph.D. | Chief Regulatory & Quality Officer |
| Ms. P. J. Ramtin | Sr. VP of Bus. Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3152 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-10-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 22 |